Retatrutide reduced knee pain in adults with obesity and knee osteoarthritis, according to research published in the New England Journal of Medicine on November 8, 2026.
Two-thirds of participants receiving the drug saw knee pain drop by at least 50 percent. This compares to 38 percent of those who received a placebo, Medicalxpress reported.
The experimental once-weekly injectable drug was developed by Eli Lilly. It lowered both body weight and pain scores across two phase 3 clinical trials.
“Participants had remarkable responses,” said Schnitzer.
Retatrutide targets three receptors to drive weight loss
Retatrutide functions as a triple-receptor agonist. It targets the G-protein-coupled receptors for glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide, and glucagon, Healio reported.
The drug showed more weight loss than existing GLP-1 medications like semaglutide or tirzepatide. In the phase 3 trials of 2,339 randomized participants, retatrutide users achieved 20 percent to 25 percent weight loss, Medicalxpress reported. Other drugs typically result in 10 percent to 20 percent weight loss.
A separate phase 2 trial involving participants with obesity showed that 12 mg of once-weekly subcutaneous retatrutide resulted in a mean weight reduction of 24.2 percent at 48 weeks and improved multiple cardiometabolic measures, including systolic and diastolic blood pressure, waist circumference, lipid levels, and glycated hemoglobin, Healio reported.
| Retatrutide Dosage Group | Mean Body Weight Change | Placebo Group Change |
|---|---|---|
| 4-mg dose | −17.6% | −3.9% |
| 9-mg dose | −23.7% | −3.9% |
| 12-mg dose | −25.0% | −3.9% |
Pain scores drop in osteoarthritis patients
Researchers evaluated participants with knee osteoarthritis using the Western Ontario and McMaster Universities Arthritis Index (WOMAC) pain scale. In the TRIUMPH-4 trial, 445 participants were followed for 68 weeks, PubMed reported.
The 9-mg dose group showed a mean WOMAC pain score change of -3.96. The 12-mg dose group showed a change of -3.74. The placebo group showed a change of -2.12, PubMed reported.
Under the intention-to-treat (ITT) estimat for the TRIUMPH-4 trial, the differences from placebo were -1.70 (95% CI, -2.19 to -1.22) for the 9-mg dose. The difference was -1.38 (95% CI, -1.91 to -0.85) for the 12-mg dose, PubMed reported.
Beyond weight and pain, the studies noted other improvements, including reduced blood pressure, lower lipid levels, and decreased systemic inflammation, Medicalxpress reported.
Patients stopped treatment due to adverse effects
Trials monitored for treatment discontinuation and adverse effects. Discontinuation occurred in 4.1% of patients in the 4-mg group and 6.5% in the 9-mg group, Healio reported.
In the 12-mg group, 11.1% of patients stopped treatment. The placebo group had a 4.6% discontinuation rate, Healio reported.
Common adverse events related to the intervention included constipation, diarrhea, and nausea, Healio reported.
Researchers investigate anti-inflammatory effects
Scientists are looking into whether the drug’s benefits stem solely from weight loss. They want to know if the medication itself influences joint health through other means.
“That would be the goal here to say you can reduce people's pain, and you can stop the progression of their osteoarthritis,” Schnitzer said.
Data suggests GLP-1 analogues may possess anti-inflammatory effects, Futura reported.
Future studies may need to evaluate changes in physical function, muscle mass, strength, structural modifications in the joints, and inflammatory markers, according to the research findings, Futura reported.
The development of this drug by Eli Lilly builds on a long history for the Indianapolis-based company, which was founded in 1876 by a pharmaceutical chemist and Union army veteran. The company was the first to mass-produce both insulin and the polio vaccine.
In November 2025, Eli Lilly became the first health-care company in the world to reach a $1 trillion market capitalization.
The study included adults without diabetes who had a body-mass index of at least 27 and painful knee osteoarthritis. The drug is being tested for obesity, knee osteoarthritis, and moderate to severe obstructive sleep apnea, but it has not yet received regulatory approval, according to the reported findings.